Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Next Previous
Search
Trial Profile

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Monalizumab (Primary) ; Durvalumab
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innate Pharma

Most Recent Events

  • 11 May 2023 Status changed from active, no longer recruiting to completed.
  • 16 Nov 2021 According to an Innate Pharma media release, the company will present data from the Phase 2 expansion cohort ,as a mini oral presentation at the ESMO Immuno-Oncology (ESMO-IO) conference in December 2021.
  • 08 Feb 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top